UCB's Phase III lupus failure casts further shadow over field
This article was originally published in Scrip
UCB's leading lupus drug, epratuzumab, has failed to meet primary endpoints in two Phase III trials – an event which could deter future investment from this historically tricky development space.
You may also be interested in...
Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.